IQVIA™ Real-World Insights Bibliography

Patient and caregiver indirect costs after acute cardiovascular events in Europe.
Author(s): Sidelnikov E1, Gerlier L2, Kutikova L1, Amarenco P3, Kotseva K4, Annemans L5
Affiliations(s): 1 Amgen (Europe) GmbH, Zug, Switzerland 2 IQVIA, Zaventem, Belgium 3 Paris-Diderot-Sorbonne University, Paris, France 4 National Heart & Lung Institute, Imperial College London, London, UK 5 Ghent University, Ghent, Belgium
Publication(s):  ISPOR 21st Annual European Congress, 2018, November 10-14, Barcelona, Spain
Document Type(s): Oral presentation,
Countries: Austria, Bulgaria, Croatia, Czech, Denmark, Finland, Germany, Greece, Italy, Norway, Romania, Slovakia, Slovenia,
Click here for the abstract
C:
Y:
Cardiovascular disease, Health economics,
2018
  L:
A:
English
Burden of illness, Cost of illness,
  Add to report
 
 
Feasibility Assessment for Conducting a Multi-Country Post-Marketing Safety Oncology Study Using Secondary Data Sources in Europe
Author(s): Wells KE, Jiang R, Tyczynski JE, Secrest M, Oliveria SA
Affiliations(s): Wells KE: IQVIA; Jiang R: Abbvie; Tyczynski JE: Abbvie; Secrest M: IQVIA; Oliveria SA: IQVIA
Publication(s):  34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management
Document Type(s): Abstract,
Countries: Denmark, Finland, Germany, Norway, Sweden, UK,
C:
Y:
Database Validity and methodology, Oncology, Patient Registries & Real-World Study Methods,
2018
  L:
A:
English
Database Study, Epidemiological study, Retrospective cohort analysis, Retrospective database analysis, Review,
  Add to report
 
 
Different patterns of second?line treatment in type 2 diabetes after metformin monotherapy in Denmark, Finland, Norway and Sweden (D360 Nordic): A multinational observational study
Author(s): Persson F, Bodegard J, Lahtela JT, Nyström T, Jørgensen ME, Jensen ML, Gulseth HL, Thuresson M, Hoti F, Nathanson D, Norhammar A, Birkeland KI, Eriksson JG, Eriksson JW
Affiliations(s): StatFinn & EPID Research, Espoo, Finland
Publication(s):  Endocrinol Diabetes Metab.
Document Type(s): Article,
Countries: Denmark, Finland, Norway, Sweden,
Click here for the abstract
C:
Y:
Diabetes,
2018
  L:
A:
English
Population Based Study, Retrospective database analysis,
  Add to report
 
 
COMMONALITIES AND DIFFERENCES IN DATA COLLECTION ACROSS EUROPEAN SPONDYLOARTHRITIS REGISTRIES
Author(s): M. L. Hetland* 1, M. Østergaard1, J. Askling2, C. Gabay3, D. Nordstrom4, O. FitzGerald5, M. Hernández Miguel6, M. Santos7 , Z. Rotar8, H. Mann9, F. Iannone10, M. J. Nissen3, E. Hauge1, J. Gomez-Reino11, F. Díaz-González12, M. Tomsic8, K. Pavelka9, F. O'Shea5, C. Sullivan5, M. van de Sande13, I. E. van der Horst-Bruinsma13, G. J. Macfarlane14, G. T. Jones14, B. Gudbjørnsson15, T. K. Kvien16 on behalf of EuroSpA Study Group
Affiliations(s): 1DANBIO, Glostrup, Denmark, 2ARTIS, Stockholm, Sweden, 3SCQM, Geneva, Switzerland, 4ROB-FIN, Helsinki, Finland, 5ASRI, Dublin, Ireland, 6BIOBADASER, Barcelona, Spain, 7reuma.pt, Almada, Portugal, 8biorx.si, Ljubljana, Slovenia, 9ATTRA, Prague, Czech Republic, 10GISEA, Bari, Italy, 11BIOBADASER, Santiago, 12BIOBADASER, Santa Cruz de Tenerife, Spain, 13ARC, Amsterdam, Netherlands, 14BSRBR-AS, Aberdeen, United Kingdom, 15ICEBIO, Reykjavik, Iceland, 16NORDMARD, Oslo, Norway
Publication(s):  EULAR, Madrid, 2017
Document Type(s): Abstract,
Countries: Czech, Denmark, Finland, Ireland, Italy, Norway, Slovenia, Spain, Sweden, Switzerland,
Click here for the abstract
C:
Y:
Rheumatology,
2017
  L:
A:
English
Epidemiological study,
  Add to report
 
 
Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature.
Author(s): Svedman FC1, Pillas D2, Taylor A2, Kaur M2, Linder R3, Hansson J1.
Affiliations(s): 1Department of Oncology-Pathology, Karolinska Institutet, Karolinska University Hospital Solna, Stockholm, Sweden. 2Centre for Observational Research, Amgen Ltd, Uxbridge, UK. 3IMS Health Sweden, Stockholm, Sweden.
Publication(s):  Clinical Epidemiology
Document Type(s): Article,
Countries: Australia, Austria, Belgium, Bulgaria, Croatia, Czech, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Serbia and Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, UK,
Click here for the abstract
C:
Y:
Oncology,
2016
  L:
A:
English
Literature Review,
  Add to report
 
 
Use of Contraindicated Drugs in Pediatric Outpatients in the Nordic Countries
Author(s): Prami T, Långström D, Iso-Mustajärvi I, Sandler N
Affiliations(s): EPID Research, Espoo, Finland
Publication(s):  Pharmacoepidemiology and Drug Safety (2016):25 (S3): pp. 3-679
Document Type(s): Abstract,
Countries: Denmark, Finland, Norway, Sweden,
Click here for the abstract
C:
Y:
Pediatrics,
2016
  L:
A:
English
Retrospective database analysis,
  Add to report
 
 
Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study.
Author(s): Emery P1, Gottenberg JE2, Rubbert-Roth A3, Sarzi-Puttini P4, Choquette D5, Taboada VM6, Barile-Fabris L7, Moots RJ8, Ostor A9, Andrianakos A10, Gemmen E11, Mpofu C12, Chung C13, Gylvin LH12, Finckh A14.
Affiliations(s): 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Chapel Allerton Hospital, Leeds, UK NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK. 2Department of Rheumatology, CHU Strasbourg, Strasbourg, France. 3University of Cologne, Cologne, Germany. 4L Sacco University Hospital, Milan, Italy. 5University of Montreal, Montreal, Canada. 6Facultad de Medicina, Hospital Universitario Marqués de Valdecilla, Universidad de Cantabria, Santander, Spain. 7Hospital de Especialidades Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, México City, Mexico. 8Department of Rheumatology, University of Liverpool, Liverpool, UK. 9Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. 10Hellenic Foundation for Rheumatological Research, Athens, Greece. 11Quintiles, Rockville, Maryland, USA. 12F Hoffmann-La Roche Ltd, Basel, Switzerland. 13Genentech Inc, San Francisco, California, USA. 14University Hospital of Geneva, Geneva, Switzerland.
Publication(s):  Ann Rheum Dis. 2015 Jun;74(6):979-84
Document Type(s): Article,
Countries: Canada, Colombia, France, Germany, Greece, Italy, Mexico, Norway, Portugal, Spain, UK,
Click here for the abstract
C:
Y:
Comparative Effectiveness & Health Technology Assessment, Rheumatology,
2015
  L:
A:
English
Clinical setting: hospital, clinical setting: Secondary care, Prospective study, RWLPR (Real-World Late Phase Research-quintiles,
  Add to report
 
 
Health economic evaluation of canagliflozin in the treatment of type 2 diabetes mellitus in Norway
Author(s): Troelsgaard A1, Huetson P2, Kjellberg J3, Hemels M1, Knudsen M4
Affiliations(s): Janssen A/S, Birkerød, Denmark, 2IMS Health, Stockholm, Sweden, 3Zefferin Farma AB, Stockholm, Sweden, 4IMS Health, Hellerup, Denmark
Publication(s):  ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands
Document Type(s): Poster,
Countries: Norway,
C:
Y:
Diabetes,
2014
  L:
A:
English
Economic evaluation,
  Add to report
 
 
Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study.
Author(s): Jose´ R. Banegas 1,2*, Esther Lo´pez-Garcı´a 1,2, Jean Dallongeville3, Eliseo Guallar 4,5,6,7, Julian P. Halcox8, Claudio Borghi 9, Elvira L. Masso´-Gonza´lez 10, Francisco J. Jime´nez 11, Joep Perk12, Philippe Gabriel Steg13, Guy De Backer 14,and Fernando Rodrı´guez-Artalejo1,2
Affiliations(s): 1 Department of Preventive Medicine and Public Health, School of Medicine, Universidad Auto´noma de Madrid/IdiPAZ, Avda Arzobispo Morcillo, 2, 28029 Madrid, Spain; 2 CIBER of Epidemiology and Public Health, Madrid, Spain; 3 Inserm U 744, Institut Pasteur de Lille, 59019 Lille Cedex, France; 4 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 5 Department of Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 6 Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA; 7 Department of Cardiovascular Epidemiology and Population Genetics, National Center for Cardiovascular Research (CNIC), Madrid 28029, Spain; 8 Wales Heart Research Institute, Cardiff University, Heath Park, Cardiff CF14 4XN, UK; 9 Department of Internal Medicine, Aging and Clinical Nephrology, University of Bologna, Bologna, Italy; 10Medical Department, AstraZeneca Farmace´utica Spain, S.A., 28003 Madrid, Spain; 11Medical Department, AstraZeneca Europe, 1935 Zaventem, Belgium; 12School of Health and Caring Sciences, Linnaeus University, 391 82 Kalmar, Sweden; 13INSERM U 698, Assistance Publique–Hoˆpitaux de Paris and Universite´ Paris-Diderot, Paris, France; and 14Department of Public Health, University of Gent, 9000 Gent, Belgium
Publication(s):  Eur Heart J. 2011 Sep;32(17):2143-52
Document Type(s): Article,
Countries: Austria, Belgium, France, Germany, Greece, Norway, Spain, Sweden, Switzerland, Turkey, UK,
Click here for the abstract
C:
Y:
Cardiovascular disease,
2011
  L:
A:
English
Observational study, Prospective study,
  Add to report
 
 
Excess risk attributable to traditional cardiovascular risk factors in clinical practice settings across Europe - The EURIKA Study.
Author(s): Guallar E, Banegas JR, Blasco-Colmenares E, Jiménez FJ, Dallongeville J, Halcox JP, Borghi C, Massó-González EL, Tafalla M, Perk J, De Backer G, Steg PG, Rodríguez-Artalejo F.
Affiliations(s): 
Publication(s):  BMC Public Health. 2011 Sep 18;11:704. doi: 10.1186/1471-2458-11-704.
Document Type(s): Article,
Countries: Austria, Belgium, France, Germany, Greece, Norway, Russian Federation, Spain, Sweden, Switzerland, Turkey, UK,
Click here for the abstract
C:
Y:
Cardiovascular disease,
2011
  L:
A:
English
Observational study, Prospective study,
  Add to report
 
 
 1 of 2 Next Page Last Page